Stem Cell Sciences Shareholders Support Sale to StemCells | GenomeWeb

NEW YORK (GenomeWeb News) – Shareholders of UK-based Stem Cell Sciences have voted in favor of selling the firm's assets to Stem Cell Sciences.

The vote is the most recent step in SCS' plans to sell off its assets and delist from the AIM and Australian Securities Exchange.

The firms announced the nearly $5 million deal earlier this month.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.